Question · asked by 1 review
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids): Disease severity, as measured by validated, patient‐reported symptom score
- Population
- patients with chronic rhinosinusitis with nasal polyps
- Intervention
- Anti‐IgE mAb (omalizumab)
- Comparison
- placebo (on top of topical steroids)
- Outcome
- Disease severity, as measured by validated, patient‐reported symptom score
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids) Disease severity, as measured by validated, patient‐reported symptom score · patients with chronic rhinosinusitis with nasal polyps The review found no eligible studies for this question. Biologics for chronic rhinosinusitis (2021) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.